Liposomal Bupivacaine is Not Associated with a Higher Rate of Surgical Site Infections

Veterinary Vertex

Send us a Text Message.

Ever wondered if advanced pain relief for pets could compromise their recovery from surgery? That's the burning question we tackle with Drs. Camille Andrews and Rachel Williams as they unpack the results of their study on liposomal bupivacaine, or Nocita, in dogs and cats undergoing gastrointestinal surgery. Camille and Rachel discuss how Nocita measures up to the veterinary community's expectations, squashing fears of increased surgical site infections or the emergence of antibiotic-resistant superbugs. We get the inside scoop on the motivations behind this research, from Nocita's 72-hour pain relief window to addressing off-label usage concerns to considering the financial aspect for pet owners. You won't want to miss this important episode!
JAVMA article: https://doi.org/10.2460/javma.23.08.0463

INTERESTED IN SUBMITTING YOUR MANUSCRIPT TO JAVMA ® OR AJVR ® ?

JAVMA ® : https://avma.org/JAVMAAuthors

AJVR ® : https://avma.org/AJVRAuthors
FOLLOW US:
JAVMA ® :

Facebook: Journal of the American Veterinary Medical Association - JAVMA | Facebook

Instagram: JAVMA (@avma_javma) • Instagram photos and videos

Twitter: JAVMA (@AVMAJAVMA) / Twitter

AJVR ® :

Facebook: American Journal of Veterinary Research - AJVR | Facebook

Instagram: AJVR (@ajvroa) • Instagram photos and videos

Twitter: AJVR (@AJVROA) / Twitter
JAVMA ® and AJVR ® LinkedIn: https://linkedin.com/company/avma-journals

Chapters

1. Liposomal Vipivacaine and Surgical Site Infections (00:00:00)

2. Preparation and Communication in Scientific Writing (00:07:10)